Literature DB >> 33664590

Multi-Omics Characterization and Origin Assessment of Bilateral Lung Adenoid Cystic Carcinoma: A Case Report.

Minhua Ye1, Sijia Ren2, Chunguo Wang1, Xiaoshun Shi3, Jianfei Shen1.   

Abstract

BACKGROUND: Primary adenoid cystic carcinoma (ACC) of the lung, which arises from the bronchial gland and is rare, accounting for only 0.04-0.2% of all primary lung tumors. The genetic profiling of bilateral ACC of unknown primary site and application in postoperative decision-making are less reported. CASE
PRESENTATION: A 57-year-old male with a smoking history of over 30 years and multiple nodules in both lungs was present to our department. After assessing the bilateral solid nodules in his Positron Emission Tomography-Computed Tomography (PET/CT) scan, malignant lesions at the left lower lung, right lower lung, and right middle lung are suspected. Sequential selective video-assisted thoracoscopic surgeries (VATS) were performed. A genetic alteration test of 425 cancer-related genes and global gene expression profile of the specimens revealed intrapulmonary metastasis existed. The patient was followed up for three years without recurrence and tissue mutations in liquid biopsy.
CONCLUSION: We present a way of omics-based multiple pulmonary lesions origin assessment, facilitating post-operative differential diagnosis and treatment decision for difficult cases.
© 2021 Ye et al.

Entities:  

Keywords:  PIK3R1; adenoid cystic carcinoma; lung cancers of unknown primary site; next-generation sequencing

Year:  2021        PMID: 33664590      PMCID: PMC7921630          DOI: 10.2147/CMAR.S292789

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


Background

Adenoid cystic carcinoma (ACC) is a malignant tumor that often occurs in the salivary glands, but it can also originate in breast, skin, upper digestive tract and lungs.1,2 According to the World Health Organization (WHO) classification of lung cancer, salivary gland tumors can be divided into mucoepidermoid carcinoma, adenoid cystic carcinoma, epithelial-myoepithelial carcinoma and pleomorphic carcinoma.3 Primary adenoid cystic carcinoma of the lung, which arises from the bronchial gland, is rare and accounts for only 0.04–0.2% of all primary lung tumors.4,5 Because of its low incidence, its clinicopathological features, mutational and gene expression profile, treatment and long-term survival have not been fully clarified. Studies have shown that more than 90% of ACC occurs in the trachea and main bronchus, and there are even fewer cases of peripheral lung ACC, in subsegmental bronchi.6 Routine pathological examination of ACC, those in peripheral lungs with multiple lesions in both lungs sometimes can not be distinguished between multiple primary and metastatic lungs. For multiple synchronous ACCs in lungs, differentiation between multiple primary lesions and intrapulmonary metastasis is often a conundrum for post-operative staging and management.

Case Report

A 57-year-old male with a smoking history of over 30 years and multiple nodules in both lungs was present to our department. After assessing the bilateral solid nodules in his Positron Emission Tomography–Computed Tomography (PET/CT) scan, malignant lesions at the left lower lung, right lower lung, and right middle lung are suspected. Without surgical contraindication, wedge resection by video-assisted thoracoscopic surgery (VATS) was first applied to the left lower lobe’s nodule. The postoperative pathological of the left lower nodule (LLL) confirmed adenoid cystic carcinoma (ACC). Two months later, the procedure was used again to nodules in the right middle lobe (RML) and right lower lobe (RLL). Adenoid cystic carcinoma was confirmed in all lesions. Unfortunately, the pathological distinction between primary and metastatic lesions is unclear, impeding personalised decision of postoperative treatment and follow-up plans. At first, clinical approved 425 cancer-relevant genes capture-based NGS test was done for all three pulmonary lesions (GeneseeqPrime) and genomic alterations among the lesions were compared (Table 1, ). The oncoplot for genetic alterations show that MCL1 gene amplification was detected in the LLL lesion. For the shared frameshift mutation in exon 2 of PIK3R1 gene p.I68Yfs*8 were detected in LLL and RML lesions, it implies a role in tumorigenesis and metastasis from left to right side (Figure 1).
Table 1

Genetic Alterations in the Three Adenoid Cystic Carcinomas

SampleMutation TypeGeneAAChangeRefAltInterVar ClassificationCosmic ID
LLLMutantPIK3R1c.201dup (p.I68Yfs*8)TLikely pathogenic
MutantLYNc.1079G>A (p.R360Q)GAUncertain significance
MutantSPOPc.361C>T (p.R121W)GAUncertain significanceCOSM2698401
MutantSETD2c.4929C>G (p.N1643K)GCUncertain significance
MutantFBXW7c.1034C>T (p.T345I)GAUncertain significanceCOSM6993417; COSM6993415; COSM6993414; COSM6993416; COSM6993412; COSM6993413
CNVMCL1
MSMSS
TMB
RMLMutantPIK3R1c.201dup (p.I68Yfs*8)TLikely pathogenic
MSMSS
TMB
RLLMSMSS
TMB
BloodSNPDPYDc.1627A>G (p.I543V)TCBenignCOSM3747121
SNPERCC1c.354T>C (p.N118=)AGBenign
SNPERCC2c.2251A>C (p.K751Q)TGBenignCOSM4132125
SNPNQO1c.559C>T (p.P187S)GAUncertain significanceCOSM148097
SNPTYMS 6bpc.*450_*455delAAGTTATTAAAGBenign
SNPUGT1A1c.211G>A (p.G71R)GAUncertain significanceCOSM4415617; COSM4415616
SNPGSTT1
TMB

Notes: *COSMIC, the Catalogue of Somatic Mutations in Cancer; InterVar, a bioinformatics software tool for clinical interpretation of genetic variants by the ACMG/AMP 2015 guideline, defining variants into “Benign”, “Likely benign”, “Uncertain significance”, “Likely pathogenic” and “Pathogenic”, together with detailed evidence code.

Figure 1

Genetic alterations of the presented multiple ACC lesions.

Genetic Alterations in the Three Adenoid Cystic Carcinomas Notes: *COSMIC, the Catalogue of Somatic Mutations in Cancer; InterVar, a bioinformatics software tool for clinical interpretation of genetic variants by the ACMG/AMP 2015 guideline, defining variants into “Benign”, “Likely benign”, “Uncertain significance”, “Likely pathogenic” and “Pathogenic”, together with detailed evidence code. Genetic alterations of the presented multiple ACC lesions. Recently, it has been reported that gene expression profiling can distinguish primary and metastatic lesions in varied cancer types.7–9 To further assess the origin and the relationship of these lesions, we profiled their global gene expression using the Affymetrix GeneChip® PrimeViewTM Human Gene Expression Array. Transcriptomic data from resected paracancerous lung, LLL, RML, and RLL tissue revealed their intrinsic relationship. A total of 2262 differential genes against control tissue are shared among three ACC samples, but the number of differential genes is imbalanced between the left and right lung (Figure 2A). Further coexpression analysis of gene expression within groups showed distinct expression patterns between normal and cancer tissue while a close relationship among cancer samples is observed, indicating intrinsic similarities among ACC samples (Figure 2B). Next, principal component analysis on differentially expressed genes further confirmed that the transcriptomic similarity is transitionally higher between RML and RLL compared with RML and LLL, suggesting right-side lesion could be derived from the left-side lesion (Figure 2C). The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis on the top 200 differential genes by clusterProfiler revealed metastasis-associated cell pathways (focal adhesion, PI3K-Akt signaling pathway, and ECM–receptor interaction) are progressively activated from left tumor tissue to right tumor tissues (Figure 2D). We also observed similar transition in Gene Ontology overlapping based on the top 10 terms of biological process, molecular function and cellular component (Table 2). Taken together, the mutation characteristic, gene expression similarity, and cell signaling shift indicate that this patient had a left-side primary peripheral pulmonary ACC with contralateral lung metastasis.
Figure 2

Transcriptome-assisted origin assessment of multiple ACC lesions. (A) The Venn diagram visualized the number of differential gene expression in the three tumors. (B) Heatmap of differential gene expression correlation matrices. (C) Hierarchical clustering and principal component analysis of gene expression profile. (D) KEGG signaling pathway analysis of DEGs in three tumors. Cells in green indicate the signaling pathways are significantly enriched, while cells in red mean the pathways are not activated.

Table 2

Overlapped Top 10 Upregulated GO Terms in the Three Malignant Tumours

TermDescriptionP-value in RMLP-value in RLLP-value in LLLOverlap Enrichment
Biological Process
GO:006351Transcription, DNA-templated4.09114E-063.34546E-07Unique in right lesions
GO:0006355Regulation of transcription, DNA-templated7.11726E-063.61249E-07Unique in right lesions
GO:0002934Desmosome organization2.58612E-055.49273E-07Unique in right lesions
GO:0030198Extracellular matrix organization9.67886E-064.76496E-06Transitional
GO:0007155Cell adhesion1.77278E-059.73916E-06Unique in right lesions
Molecular Function
GO:0003677DNA binding1.78152E-065.66698E-080.000783362Common Enrichment
GO:0000166Nucleotide binding0.000581135.7697E-060.002607564Common Enrichment
GO:0005515Protein binding1.16842E-093.0942E-107.03011E-05Common Enrichment
GO:0003700Transcription factor activity, sequence-specific DNA binding6.32364E-061.68874E-054.56837E-06Common Enrichment
GO:0030020Extracellular matrix structural constituent conferring tensile strength0.0001345920.000487548Transitional
GO:0046872Metal ion binding0.0012714160.001801895Transitional
Cellular Component
GO:0005654Nucleoplasm8.01633E-108.15503E-100.002022821Common Enrichment
GO:0005634Nucleus7.03725E-101.98908E-095.51924E-09Common Enrichment
GO:0045178Basal part of cell0.0007179970.000607947Transitional
GO:0071944Cell periphery0.0001260157.75437E-05Transitional
GO:0005592Collagen type XI trimer0.0023241110.00088074Transitional
GO:0005730Nucleolus1.78313E-070.002198699Unique in right lesions

Abbreviations: GO, Gene Ontology; LLL, left lower lobe; RML, right middle lobe; RLL, right lower lobe.

Overlapped Top 10 Upregulated GO Terms in the Three Malignant Tumours Abbreviations: GO, Gene Ontology; LLL, left lower lobe; RML, right middle lobe; RLL, right lower lobe. Transcriptome-assisted origin assessment of multiple ACC lesions. (A) The Venn diagram visualized the number of differential gene expression in the three tumors. (B) Heatmap of differential gene expression correlation matrices. (C) Hierarchical clustering and principal component analysis of gene expression profile. (D) KEGG signaling pathway analysis of DEGs in three tumors. Cells in green indicate the signaling pathways are significantly enriched, while cells in red mean the pathways are not activated. Since primary pulmonary ACC is a low-grade malignant tumor, surgical treatment of patients with early lung adenoid cystic carcinoma is preferred. Due to the small size and complete removal of the tumors, chemotherapy and radiotherapy after complete resection is not considered. However, due to our suspicion of intrapulmonary metastatic ACC in this patient, a closer follow-up schedule based on translationally assisted by multi-omic information was prescribed. Fortunately, the patient was followed up for three years without recurrence, and the mutations detected in tumors were not found in blood by the same 425 cancer-relevant genes NGS panel.

Discussion

Primary pulmonary ACC is a low-grade malignant tumor, which usually occurs in the main bronchus, and peripheral type is rare. This patient had multiple adenoid cystic carcinomas in both lungs. But imaging and pathological examination cannot determine the relationship among the three lesions. In contrast to the diagnose of multiple pulmonary lesions with different histological types, it is still a challenge to differentially diagnose multiple lung cancers with similar histological findings. Studies have pointed out that molecular genetic analysis of gene mutation sites can assist the origin assessment.10 The shared somatic alterations in left lower and right middle lobe lesions suggesting metastases had happened, possibly driving by PIK3R1 mutation that is frequently mutated in tumors.11 Moreover, in next step we detected low PIK3R1 mRNA level in left lower lobe lesion, low PIK3R1 mRNA level is associated with high-risk for stage I non-small cell lung cancers recurrence.12 Of note, PIK3R1 mutations have been reported in a variety of tumors, understanding its prevalence and biological function is of great significance for the development of new targeted drugs in the future, such as breast cancer.13 Based on these findings, poor-documented gene expression of ACC profile, and the request of personalised post-operative decision-making, we performed second-stage investigation of this case. In 1995, Schena et al published a report on gene chip for the first time, proving that cDNA microarray can provide a useful link between human gene expression and clinical medicine.14 Now it has been widely used in tumor research, especially in the studies of tumor metastasis. In recent years, more and more researches have applied gene expression profiling to screen pathogenic genes and to study the mechanism of tumor metastasis. It has been reported that gene expression profiling can distinguish between primary papillary thyroid carcinoma and metastatic carcinoma, primary lung carcinomas and intrapulmonary metastases and primary and metastatic melanoma.7–9 In order to solve our real-world problems, we analyzed the gene expression profiles of three lesions in the same batch to find out the differences in gene expression levels and signal pathways among the three tumor lesions. We found that there is a significant difference in gene expression between left lower lung lesions and right-side lung lesions. At the same time, KEGG pathway analysis showed that the differential genes in the right tumor were mainly enriched in PI3K-Akt signaling pathway. It is worth mentioning that PI3K-Akt signaling pathway is closely related to tumor metastasis. Studies have shown that primary tumor cells activate this signaling pathway to cause tumor metastasis.15,16 As indicated above, we speculate that the left tumor is the primary tumor and the right lung tumors are the metastatic lesions, indicating that this patient is a primary peripheral pulmonary ACC with contralateral lung metastasis. Adenoid cystic carcinoma of the lung is usually a long course disease, from the appearance of a lung mass to the patient’s onset of symptoms, which can last for years to decades. Surgical treatment of patients with early lung adenoid cystic carcinoma has a good survival outcome. For patients who cannot receive surgery, local radiotherapy can be taken.17 In this patient, the size of the tumors were small, and we completely removed the lesions in sequential. Since the patient’s lesions were completely removed, supporting by no benefits from chemotherapy and radiotherapy after complete resection of lung ACC, the patient did not receive further treatment. Though there is still possible that metastasis from the RML lesion to the left side or synchronous lesions in both lobes, metastatic ACC from left lesion to the right side in this case was highly suspected. Therefore, a closer follow-up with liquid biopsy was suggested, ensuring free recurrence and metastasis in the next three years. In conclusion, studies of genetic alteration and gene expression profile are helpful to determine the relationship between multiple lung adenoid cystic carcinoma nodules, serving as a guide for precise staging and post-operative decision of synchronous bilateral of intrapulmonary metastasis of a rare malignant tumor.
  17 in total

1.  Toward predicting metastatic progression of melanoma based on gene expression data.

Authors:  Yuanyuan Li; Juno M Krahn; Gordon P Flake; David M Umbach; Leping Li
Journal:  Pigment Cell Melanoma Res       Date:  2015-04-24       Impact factor: 4.693

2.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.

Authors:  Jason C Chang; Deepu Alex; Matthew Bott; Kay See Tan; Venkatraman Seshan; Andrew Golden; Jennifer L Sauter; Darren J Buonocore; Chad M Vanderbilt; Sounak Gupta; Patrice Desmeules; Francis M Bodd; Gregory J Riely; Valerie W Rusch; David R Jones; Maria E Arcila; William D Travis; Marc Ladanyi; Natasha Rekhtman
Journal:  Clin Cancer Res       Date:  2019-08-30       Impact factor: 12.531

4.  Quantitative monitoring of gene expression patterns with a complementary DNA microarray.

Authors:  M Schena; D Shalon; R W Davis; P O Brown
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

5.  Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.

Authors:  A V Bakin; A K Tomlinson; N A Bhowmick; H L Moses; C L Arteaga
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

6.  Peripheral pulmonary adenoid cystic carcinoma with substantial submucosal extension to the proximal bronchus.

Authors:  H Inoue; A Iwashita; H Kanegae; K Higuchi; Y Fujinaga; I Matsumoto
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

7.  The double life of p85.

Authors:  Carlotta Costa; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

8.  Lung cancer.

Authors:  W D Travis; L B Travis; S S Devesa
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

9.  Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma-Do They Exist?

Authors:  Sylwia Szpak-Ulczok; Aleksandra Pfeifer; Dagmara Rusinek; Malgorzata Oczko-Wojciechowska; Malgorzata Kowalska; Tomasz Tyszkiewicz; Marta Cieslicka; Daria Handkiewicz-Junak; Krzysztof Fujarewicz; Dariusz Lange; Ewa Chmielik; Ewa Zembala-Nozynska; Sebastian Student; Agnieszka Kotecka-Blicharz; Aneta Kluczewska-Galka; Barbara Jarzab; Agnieszka Czarniecka; Michal Jarzab; Jolanta Krajewska
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

10.  Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.

Authors:  Li Chen; Liu Yang; Ling Yao; Xia-Ying Kuang; Wen-Jia Zuo; Shan Li; Feng Qiao; Yi-Rong Liu; Zhi-Gang Cao; Shu-Ling Zhou; Xiao-Yan Zhou; Wen-Tao Yang; Jin-Xiu Shi; Wei Huang; Xin Hu; Zhi-Ming Shao
Journal:  Nat Commun       Date:  2018-04-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.